Patients are finding positive benefit in the use of glucagon-like peptide 1 (GLP-1) receptor agonist drugs across a wide range of health conditions, as published in Nature Medicine. An observational study of Veterans Affairs data for nearly 2 million patients found that over about 3 years, adults with type 2 diabetes who used a GLP-1 had significantly decreased risks for 42 outcomes, increased risks for 19 outcomes, and no effect with 114 other outcomes when …
Read More